---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-24-000136"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:22:34.775701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M

## Summary
- Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.
- PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.
- Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.
- Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.
- Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001439222-24-000136
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/0001439222-24-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/agio-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-24-000136
- JSON: https://secwatch.observer/filing/0001439222-24-000136.json
- Plain text: https://secwatch.observer/filing/0001439222-24-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.